{"schema_version":"secwatch.filing_event.v1","accession":"0001022079-22-000118","form_type":"8-K","ticker":"DGX","cik":"0001022079","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2022-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.619418+00:00","generated_at":"2026-06-24T09:47:34.842303+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95","bullets":["Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).","Base business revenue $2.10B (+2.9% YoY); COVID testing revenue $355M (-30.5% YoY).","Raises FY22 guidance: net revenues $9.50B-$9.75B, adjusted EPS $9.55-$9.95 (prior $9.00-$9.50).","CEO-elect Jim Davis cites base business growth and expanded COVID molecular testing share.","Company supports SALSA legislation to fix PAMA clinical lab fee schedule cuts."],"urls":{"canonical":"https://secwatch.observer/filing/0001022079-22-000118","json":"https://secwatch.observer/filing/0001022079-22-000118.json","markdown":"https://secwatch.observer/filing/0001022079-22-000118.md","text":"https://secwatch.observer/filing/0001022079-22-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/0001022079-22-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/dgx-20220721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T09:47:34.842303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}